retatrutide grey market Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation People Are Already Taking This
Description
Respect the science

This is why the studies for CVD, chronic kidney disease (CKD), and obstructive sleep apnea (OSA) were so significant

This medications ability to address multiple aspects of metabolism and appetite control makes it particularly effective for patients who have found traditional weight loss methods challenging

The tradeoff: retatrutide appeared to show higher rates of nausea (42.4%), diarrhea (32.0%), and vomiting (25.3%) than tirzepatide or orforglipron at their top doses

If you need a live visit, you can request one
